Please login to the form below
ozanimod
This page shows the latest ozanimod news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: Brexit reshuffle brings new health minister, Celgene thalassemia success, Wellcome read to leap into future
The news is very welcome for Celgene, which has suffered numerous setbacks in recent months, including the FDA refusing to accept the filing of ozanimod in February.
Latest news
-
Daily Brief: Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more
Smith looked to have paid the price for some costly slip-ups in recent months, most notably the FDA’s refused to review Celgene’s multiple sclerosis drug, ozanimod.
-
Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more
This looks like Smith has paid the price for some costly slip-ups in recent months, most notably the FDA’s refused to review Celgene’s multiple sclerosis drug, ozanimod.
-
Morning brief: Gilead partners with Verily, Roche expands 4DMT partnership and more
new drugs, multiple sclerosis candidate ozanimod - and all because the company had failed to provide adequate non-clinical and clinical pharmacology data in its dossier.
-
FDA turns down Celgene’s filing for multiple sclerosis drug
Celgene is facing a delay for its multiple sclerosis candidate ozanimod in the US and elsewhere as the FDA has refused to accept its marketing application for the drug. ... The embarrassing setback has arisen because of deficiencies in the “nonclinical
-
Sanofi licences Principia MS drug in $805m deal
And an even bigger threat is looming in the shape of Celgene’s ozanimod, a once-daily oral therapy that GBI Research has predicted could make rapid headway thanks to a
More from news
Approximately 2 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Pharma deals in July 2015
Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of $4bn to $6bn per year. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Business Unit Head, Medical Communications, London
-
Excellent package
- Senior Project Manager - Medical Writing
-
Great salary and bebefits
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- NHS England says yes to Roche's Hemlibra
- Moving annual total (MAT)
- Roche keeps Venclexta train rolling with new leukaemia filing
- Communiqué Awards 2018: Winners in pictures - Communiqué Awards 2016
- Pfizer enters late-stage haemophilia B gene therapy trial
- Porterhouse Medical strengthens the team with three new members.
- Developing advocacy in the pharmaceutical industry.
- Roche’s Tamiflu successor hits the mark in complicated flu
- Novartis launch NET cancer community app
- J&J’s Invokana aces diabetic kidney disease trial, setting up filings
PMHub
Wordbird
Wordbird is a healthcare communications agency with creative, compelling copy at its heart....
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
